1. Introduction {#s0005}
===============

Inflammatory bowel disease (IBD) is a designation for the idiopathic chronic inflammatory gastrointestinal disorder, remains one of the major challenges for gastroenterologists and World Gastroenterology Organization (WGO). The term IBD covers Crohn's disease (CD) and ulcerative colitis (UC), and are known to affect approximately 10--20 per 100,000 people per year ([@b0145]), has a high recurrence rate and eventually lead to high morbidity. Ulcerative colitis affects the large bowel and the associated clinical manifestations include chronic hemorrhagic diarrhea, abdominal cramps and pain, gut perforation, and complete bowel obstruction, which significantly affect the quality of life of the ailing person. The precise etiology of the disease is not well recognized; however, host genetic factors, immune disequilibrium, environmental factors, and host-microbial composition are believed to be responsible for the development and progression of the disease ([@b0135], [@b0065], [@b0280], [@b0090]). Current medical interventions for managing IBD are not satisfactory and does not lead to complete remission of symptoms. Further, UC patients frequently experience relapse and conventional treatments are not sufficient to keep remission for longer durations. Failure of standard treatments for UC leads to colon removed in about 33--50% of cases. The front-line therapy for UC consists of a large derivative chain of aminosalicylates, the components actively known for their anti-inflammatory properties ([@b0235], [@b0240]). Mesalamine is a new generation formulation of 5-ASA and its clinical trials have displayed significant effectiveness for the treatment of mild to moderate form of UC ([@b0250], [@b0255]). Mesalamine along with 5-ASA lines of drugs has adverse clinical side effects, sub-grouped into dose-related intolerance effects and dose-independent idiosyncratic reactions. Clinical side effects of these drugs can lead to symptoms like regurgitation, nausea, headache, and abdominal pain, which are results of dose-related intolerance ([@b0060]). Whereas, idiosyncratic reactions include male infertility, anemia, hepatic and pulmonary dysfunction, hypersensitivity rash, worsening colitis, renal toxicity, interstitial lung disease, cardiopulmonary hypersensitivity etc ([@b0215], [@b0045]). The increased burden of the UC patients is further worsened by the limited spectrum UC curable by 5-ASA lines of drugs and their alarming side effects have placed an inevitable demand for the development of broad-spectrum, effective, and safe alternatives for the treatment of UC.

The term "probiotic" refers to the administration of live microorganisms when taken in sufficient amount (\>10^7^ CFU/mL) have a beneficial effect on the host health (Plaza-Diaz et al., 2017). Also, cellular components of these probiotic microorganisms confer health benefits ([@b0155], [@b0055]). The probiotics are taken in different forms and are believed to maintain the healthy gut function ([@b0155], [@b0270]). Additionally, probiotics are suggested as therapeutic mediators for gastrointestinal disorders and many pathologies, including inflammatory diseases ([@b0195], [@b0270]). The extract of probiotic *Lactobacillus sakei* proBio-65 has shown promising effects in treating imiquimod induced psoriasis like skin inflammation ([@b0220]). Suggesting efficacy of extract from probiotic strains, and this could be explored for the treatment of other diseases.

As a consequence of intestinal micro-flora dysbiosis, the epithelium mounts an uncoordinated and constitutively ongoing immune response, which has been linked with initiation, and the establishment of IBD. An increasing body of evidence advocates that restoration of healthy intestinal microbiota through the administration of probiotics could be beneficial for short as well as long-term management of UC. Preciously, we have reported that *L. sakei* probio65 and its extract SEL001 exhibits number of novel pharmacological effects against atopy and psoriasis ([@b0175], [@b0100], [@b0105], [@b0180], [@b0095], [@b0220]).

In this research work, we aimed to evaluate the therapeutic potential of SEL001 for its anti-inflammatory efficacy in a mouse model and its effect on gut-microbiota composition.

2. Materials and methods {#s0010}
========================

2.1. Chemicals and reagents {#s0015}
---------------------------

For extraction of SEL001, commercial grade ethanol was acquired from Duksan pure chemical Co. Ltd, (Gyeonggi-do, Korea). TNBS, mesalamine, and 3,3′, 5,5′-tetramethylbenzidine were acquired from Sigma-Aldrich (St. Louis, MO, USA). Trizol™ reagent was acquired from Life Technologies (Carlsbad, USA).

2.2. Experimental animals {#s0020}
-------------------------

Colitis studies were performed in 6-wk old ICR mice (n = 30) procured from Samtaco Bio Co. (Osan, Korea). Mice were maintained in a regulated facility of 22 ± 2 °C temperature, 55 ± 10% relative humidity and were exposed to a 12-h cycle of light and dark. Further, two groups of mice; control and treatment were marked, and each group consisted six mice. All the mice were fed on a standard rodent diet and had regular access to water. The Animal Ethical Committee of the Yeungnam University (Gyeongsan, Korea) approved the approval for research (YNU-ANETCOMM-2015-00120).

2.3. Preparation of SEL001 {#s0025}
--------------------------

The preparation and chemical composition of SEL001 was carried out by the method described in our previous study ([@b0220]). Briefly, *Lactobacillus sakei* Probio65 was cultured for 48 h in De Man, Rogosa and Sharpe (MRS) medium. Then the culture was assorted with commercial grade ethanol (1:2 ratio). Further, the combination was incubated at room temperature for 6 h with constant shaking at 150 rpm followed by centrifugation for 10 min centrifuged at 8000*g*. Finally, supernatant was carefully collected, filtered (whatman No. 1) and freeze dried. A detailed chemical composition profile of ethanolic extract of a probiotic strain *L. sakei* probio65 (SEL001) has been summarized in [Table 2](#t0010){ref-type="table"}. The results are described in our previous publication ([@b0220]).

2.4. Colitis induction in experimental mice and treatments {#s0030}
----------------------------------------------------------

Colitis induction procedure followed in this study was similar as described by the [@b0165]. In brief, mice were allowed to fast for 24 h before induction of colitis and subsequent therapeutic treatments. Mice were exposed to light anesthesia-using diethyl ether and then exposed to the intra-rectal administration of 0.6 mg of TNBS in 0.1 ml of 30% ethanol using a trocar needle for colitis induction. A polyethylene catheter was introduced intra-rectally 4--5 cm into the distal part of the colon, which was followed by intraluminal application of a calculated dose of TNBS for colitis induction. Each mouse was hold in head-down positing for sixty seconds to ascertain proper distribution of TNBS within the entire colon and cecum and avoid leakage of the solution. Following a similar procedure, mice (n = 12) were similarly randomized in two control groups consists of 6 mice in each group; the first control group (n = 6) without TNBS induction, designated as healthy, received sterile water intra-rectally on day 0, and second control group (n = 6) received 0.1 ml of 30% ethanol (EtOH).

Twenty-four hours post-TNBS application, mice were randomized to three oral-treatment protocols; vehicle-saline (untreated group n = 6), 5-ASA (n = 6) and freeze-dried ethanolic extract (SEL001; 50 mg/kg; n = 6) for 7 days. The healthy control group (n = 6) received water at consequent interims that paralleled to treatment protocols. Mice were routinely inspected for their behavioral output and body mass. Mice were sacrificed with an overdose of diethyl ether at the end of day 7.

2.5. Myeloperoxidase (MPO) activity assay {#s0035}
-----------------------------------------

Myeloperoxidase (MPO), a marker for neutrophil infiltration of tissues represent a measure of severity caused by colonic inflammation. The peroxidase activity was checked using 3,3′, 5,5′-tetramethylbenzidine (TMB) reagent as a colorimetric substrate ([@b0050]). Briefly, a 3 cm colonic segment was homogenized, followed by centrifugation at 10,000 rpm for 10--15 mins. The pellet obtained was retained and used for the measurement of MPO activity. The MPO activity was expressed as units per 3 cm of the colon.

2.6. Clinical and histological evaluation of colitis {#s0040}
----------------------------------------------------

Clinical assessment of TNBS induced colitis included a routine monitoring of changes in body weight and diarrhea for each mouse. The entire colon was sampled for post-mortem clinical assessment of parameters such as variation in colon length, and colon weight across for all treatment groups.

The colonic injury was further assessed through histological and histomorphometric examinations. Crossly trimmed colonic tissue sections, 6--7 cm proximal to the rectum are excised, and then fixed in 10% neutral buffered formalin phosphate for 24 h. In order to address the extent of inflammation, the paraffin-embedded tissue sections (3--4 μm) were stained with hematoxylin and eosin (H&E), and toluidine blue staining for microscopic quantification of mast cell population ([@b0180], [@b0185], [@b0225]). The degree of fibrosis was examined by staining the transverse colonic sections with Masson's trichome method ([@b0105]). Further, histological profiles of stained colonic tissue samples were examined under a light microscopy (Axio Oser Z1, Germany; magnification 6200), and then scored by pathologists, unaware to the experimental groups. The microscopic features were evaluated on a scale established by [@b0185], [@b0225], modified from [@b0245], [@b0190]. For performing morphometric analysis of regions occupied by ulcerative lesions (%), number of infiltrated mast and inflammatory cells (cells/mm^2^ of fields), number of microvessels formed (vessels/mm^2^ of fields), and percentage of collagen tissue deposited (Masson's trichome stain; %/mm^2^ of fields), an automatic image analyzer was utilized.

2.7. DNA extraction, PCR, and sequencing {#s0045}
----------------------------------------

For microbiome analysis, the DNA extraction from the fecal samples was carried out with the help of a commercial kit, FastDNA® spin kit for soil (Qiagen Inc., Valencia, CA, USA). DNA quality was checked using 0.8% agarose. Further, the concentration of DNA (ng/μl) was checked by NanoDrop. Further, the primer was designed to target V1-V3 regions of prokaryotic 16S rRNA gene. The pre-denaturation was carried out at 95 °C for 5 min; then 30 cycles of denature for 30 s was done at 95 °C. The annealing was done at 72 °C for approximately 30 sec, followed by 5 min elongation at 72 °C. After confirmation of PCR product, the sequencing was performed on 454 pyrosequencing platform (Roche, USA) at ChunLab (South Korea).

2.8. Bioinformatic analysis {#s0050}
---------------------------

Quantitative Insights into Microbial Ecology (QIIME) pipeline (v.1.8.0; [@b0165]) was used for the analysis of sequencing data. The statistical analysis was done with R. The reads that did not match with the specific sample barcode were discarded. In addition read shorter or longer than 50 pm and 480 bp, respectively, were also discarded. Further, OTUs with 97% similarly were formed by UCLUST ([@b0035]). PyNAST was used to align both representative and reference sequences ([@b0020]). Further, taxonomic assignments and relationships between microbial communities were quantified.

2.9. RNA extraction and PCR analysis {#s0055}
------------------------------------

The RNA extraction from the colon tissue was isolated using Trizol™ reagent (Life Technologies, Carlsbad, USA) following manufacturer's instructions. The extracted RNA was stored in diethylpyrocarbonate-treated (DEPC-treated) H~2~O at --80 °C for further use. Further, the isolated RNA was reverse transcribed into cDNA using RevertAid kit (MBI, Thermo-Scientific, USA) following the manufacturer's protocol. A 20 μl reverse transcription reaction mixture consisted of 1.0 μg of RNA, then primed with oligo (dT) 20 primers. The cDNA was used for quantification and expression of various genes associated with ulcerative colitis such as CD4, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α). Furthermore, the quantitative real-time -PCR was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems, Seattle, USA) on an ABI 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was taken as an internal control. Primers for this study were designed with Primer-BLAST Software using the sequence information listed at the National Center for Biotechnology Information (NCBI). The primer sequence sets used are provided in [Table 1](#t0005){ref-type="table"}.Table 1The table shows a list of primer indicating species, gene names, product size, Tm (temperature), and primer sequences (F: forward, R: reverse).SpeciesGeneProduct size (bp)Tm (℃)Sequence (F)Sequence (R)MouseGAPDH11360.115′-gagagtgtttcctcgtcccg-3′5′-caatctccactttgccactgc-3′CD410559.895′-ccagacagtgttcctggctt-3′5′- tgcctggcgctgttgg-3′TNF-α18559.535′-ggcctccctctcatcagttc-3′5′-cacttggtggtttgctacgac-3′IL-6130595′-agtccggagaggagacttca-3′5′-gccattgcacaactcttttctca-3′Table 2The GC--MS chemical composition profile of ethanolic extract (SEL001) derived from a probiotic strain *L. sakei* probio65.SNCompoundRetention time (min)Relative peak area (%)**Organic acids**1D-lactic acid4.8433.862L-lactic acid8.526.033Propanoic acid9.7916.654Oleic acid64.460.16  **Amino acids**51,2-Bis (trimethylsiloxy) ethane6.860.306Valine54.721.127L-proline59.000.38**Phenols**8Taxicatigenin55.730.339Hexahydro-3-phenylmethyl71.200.78104-(Methylsulfanylphenyl) carbamic acid57.971.32  **Imidazole derivatives**118-Allyl-2-amino-6-methylimidazo-1,3,5-triazin16.500.9512Imidazo diazapinone65.550.35  **Sugar alcohols**13Threitol15.700.2414Glycerol21.4816.615*myo*-inositol63.151.87  **Others**161,3-Butandiol8.871.3517Pentasiloxane15.130.42183-Methyl octahydropyrrolo pyrazine50.160.5419Clemastine51.570.8820Pyrrolo\[1,2--1\] pyrazine-1,4-dione52.561.26213,6-Dioxa-2,7-disilaoctane7.331.3122Diethyldithiophosphinic acid58.960.63232,5-Piperazinedione64.630.36241,3-Bis (4-chlorobenzyl)-5,6-dihydrobenzo-quinazoline66.330.2225Dimethoxyphenyl tetrahydropyran66.950.55263-benzyl-1,4-diaza-2,5-dioxobicyclononane69.600.3327Oleamide71.020.2528Erucylamide87.070.39

2.10. Statistical analysis {#s0060}
--------------------------

All the data are expressed as ± standard error of the mean. Further, unpaired Student's *t*-test or non-parametric Mann--Whitney test was used to determine the statistical significance test differences in treatment groups. *p* values of \<0.05 were considered statistically significant.

3. Results {#s0065}
==========

3.1. Effect of SEL001 on clinical disease activity {#s0070}
--------------------------------------------------

The mice in all the treatment groups exhibited uniform and steep weight loss within first 24 h after receiving TNBS as compared with the untreated control mice. However, an initial weight loss of 5.0% was also observed in animals treated with 30% ethanol compared with untreated control mice. This initial weight loss in ethanol control group was due to a non-specific perturbation of mucosal wall by ethanol. This initial weight loss was diluted immediately after day 2, after a steady and gradual weight gain trend was noted in ethanol control group. Mice treated with TNBS continued to loose weight till 5th day post treatment. The weight loss in mice treated with TNBS was 15.0% in body mass when compared with untreated control mice. However, mice treated with standard drug 5-ASA and SEL001 displayed a divergent pattern of significant gradual weight gain as early as day 3 when compared with TNBS treated mice. The body weight data ([Fig. 1](#f0005){ref-type="fig"}a) suggested that SEL001 and 5-ASA were equally effective (*P* ≥ 0.05) in ameliorating the colonic inflammatory reaction to TNBS, thereby allowing the mice to recommence normal eating pattern and weight ([Fig. 1](#f0005){ref-type="fig"}a). Nevertheless, after 5 days a steady increase in weight gain was observed in all groups.Fig. 1Effect of oral administration of freeze-dried ethanol extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on body weight (a); colon length (b); colon weight (c); and MPO activity (d) in TNBS-induced colitis experimental mice.

The extent of damage caused by acute TNBS-induced colitis was also reflected by shortening of colon length. During 7-day course of treatment, the TNBS-treated mice exhibited approximately 50% reduction in colon length when compared to the control mice ([Fig. 1](#f0005){ref-type="fig"}b). In contrast, TNBS-treated mice showed a drastic increase of colon weight approximately by 3-fold when compared to the control mice ([Fig. 1](#f0005){ref-type="fig"}c). Both 5-ASA and SEL001 treatments resulted in a lesser (*P* \< 0.05) reduction of colon length, and a milder colon weight gain when compared to the control mice ([Fig. 1](#f0005){ref-type="fig"}b, c). This data on disease activity parameters suggest that SEL001 was as effective as 5-ASA in ameliorating the colonic inflammatory response to TNBS.

3.2. Effects of SEL001 on MPO activity {#s0075}
--------------------------------------

TNBS-induced colitis in mice resulted in significantly elevated MPO activity in the colon when measured 7 days after the induction in comparison to the healthy controls. Six days of monotherapy with either 5-ASA or SEL001 resulted in approximately a 50% reduction in MPO activity and these reduced values were similar to ethanol control group mice ([Fig. 1](#f0005){ref-type="fig"}d).

3.3. Effects of SEL001 on colonic mucosal injury and inflammation {#s0080}
-----------------------------------------------------------------

The histological examination of TNBS induced colitis tissues depicted an aggregate microscopic injury score of 14.02 ± 2.45 at 7 days post induction. Totalized microscopic colonic damage scores observed in TNBS-treated colonic tissue were significantly higher when compared with untreated control and ethanol control ([Table 3](#t0015){ref-type="table"}). However, these TNBS-induced microscopic colonic damage scores were reduced (*P* \> 0.05) upon treatment with 5-ASA or SEL001 (mean measures of colonic mucosal injury: 5.40 ± 2.30 and 6.80 ± 2.39, respectively). Moreover, the histomorphometric analysis further corroborated with previous microscopic injury score examination, where TNBS treatment resulted in deterioration of mucosal tissue and displayed a score of 25.68 ± 2.23. However, the histopathological signatures associated with TNBS-induced colitis were ameliorated by 5-ASA and SEL001 monotherapies ([Fig. 2](#f0010){ref-type="fig"}).Table 3Histomorphometrical values on the TNBS-induced colitis mice.CriteriaControl (untreated)Control (EtOH)TNBSTNBS + 5′-ASATNBS + SEL001Ulcerative lesions (%)[\*](#tblfn1){ref-type="table-fn"}2.36 ± 2.477.05 ± 1.70^ad^15.34 ± 4.75^ace^5.87 ± 1.22^bf^9.07 ± 2.36^acf^  Mucosa Thickness (μm)249.42 ± 13.15208.79 ± 9.89^ac^100.50 ± 12.03^ace^246.45 ± 36.29^ef^151.36 ± 17.78^acef^ Inflammatory cells (/mm^2^)54.20 ± 14.86227.40 ± 26.15^hj^460.40 ± 62.92^hjl^231.20 ± 28.26^hjn^343.00 ± 43.06^hjlo^ Microvessels (/mm^2^)10.80 ± 2.0517.20 ± 4.87^ik^56.80 ± 12.79^hjl^24.40 ± 3.78^hjmn^29.80 ± 5.40^hjmn^ Mast cells (/mm^2^)27.60 ± 3.5818.40 ± 2.97^ac^4.80 ± 0.84^ace^12.80 ± 1.64^acef^9.00 ± 1.58^aceg^ Collagen fibers (%)6.77 ± 3.1214.38 ± 2.04^ac^25.68 ± 2.23^ace^16.51 ± 2.25^acf^19.29 ± 2.37^acef^[^2][^3]Fig. 2Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on representative histopathological images of colon tissues (intact or TNBS-induced) in experimental mice. (a) Control (untreated), (b), Control (EtOH), (c) TNBS treated colon, (d). TNBS and 5′ASA treated colon, (e). TNBS and SEL001 treated colon. \[LU = Lumen; MU = Mucosa layer; MM = Muscularis mucosa; SL = Submucosa layer; ML = Muscle layer; TA = Tunica adventitia\]. Stains: HE = Hematoxylin-eosin; MT = Masson's trichrome; TB = Toluidine blue. Scale bars = 80 μm.

3.4. Effect on SEL001 on the gut bacterial composition {#s0085}
------------------------------------------------------

Weighted UniFrac distance was calculated as per relative abundance of operational taxonomic units (OTUs) in prokaryotic communities. In control and treated groups, substantial differences were seen in relative abundance of specific populations ([Fig. 3](#f0015){ref-type="fig"}). The taxonomic assignment of the OTUs recognized 6 major phyla across all groups. Firmicutes constituted \>95% in the control group. However, in the treated groups, the lineage of Firmicutes decreased with a concomitant increase in Bacteroidetes and Proteobacteria ([Fig. 4](#f0020){ref-type="fig"}). The relative abundance of Proteobacteria was higher in the TNBS + ASA group as compared to TNBS + SEL001 group ([Fig. 5](#f0025){ref-type="fig"}).Fig. 3Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on weighed Unifrac-Principal Coordinate Analysis (PCoA) in experimental mice.Fig. 4Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on phylum level composition of experimental mice.Fig. 5Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on phylum level composition of Proteobacteria in experimental mice.

At the genus level, 2 genera from Actinobacteria, 3 genera from Proteobacteria, 5 genera from Bacteroidetes, and 18 genera from Firmicutes was identified. Among Bacteroidetes, Bacteroides and members of Bacteroidales family S24-7 were predominant in treated groups. Conversely, members of Clostriadales (Firmicutes) were predominant (\<0.4%) in control group compared to treated group. Genus *Enterococcus* and members of the family Enterobacteriaceae (Proteobacteria) were either not detected or in a very low abundance in control group as compared to treatment groups ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on genus-level heat-map in experimental mice.

3.5. mRNA expression levels {#s0090}
---------------------------

The mRNA expression profile of pro-inflammatory cytokines such as CD4, IL-6 and TNF-α were significantly (*P* value) increased when compared with those of untreated controls, and ethanol-treated mice ([Fig. 7](#f0035){ref-type="fig"}). This increase in mRNA expression level of pro-inflammatory cytokines can be correlated with extensive cellular infiltration.Fig. 7Effect of oral administration of freeze-dried ethanolic extract (SEL001) isolated from a probiotic strain *L. sakei* probio65 on mRNA expression levels in experimental mice.

4. Discussion {#s0095}
=============

Ulcerative colitis is a persistent and long-lasting inflammatory condition that is known to affect the lining of the large bowel, predominantly the rectum ([@b0010]). Patients suffering from UC often develop inflammation in the colon and form minute open sores or ulcers that extravagate puss, and mucous. The combinatorial effect of inflammation and lesion formation culminates into severe abdominal discomfort accompanied by frequent emptying of the colon, and diarrhea. The basic pathophysiological principle behind ulcerative colitis is the impairment of normal immune system regulation towards an antigenic trigger, which leads to prolonged activation of mucosal immune response resulting in inflammation ([@b0010]).

Ulcerative colitis presents itself with a range of severities (e.g., mild, moderate, severe) that mainly influences and limits treatment options. Mesalamine (5-ASA) is a new generation aminosalicylate drug, and it has been recognized for its effectiveness against the mild-to-moderate form of UC. However, the application of 5-ASA suffers from adverse side-effects and also this drug has limited effectiveness for treating the most severe form of UC disorder ([@b0085]).

The current study demonstrated that oral administration of SEL001, which contained various bioactive components, significantly attenuated the severity of disease in a TNBS-induced colitis mouse model. These compounds or the extracts of various origins (e.g. lactic acid from *Lactobacillus*, nipa vinegar, *Gastrodia elata* root extract) exhibit anti-inflammatory effects *both in vitro* and *in vivo* ([@b0120], [@b0125], [@b0070], [@b0015]). Also, it has been confirmed that amino acids have significant therapeutic potential to control IBD ([@b0130]). In addition, the SEL001 contains *myo*-inositol, which has shown to possess anti-inflammatory effects in animal mouse model ([@b0025]); this depicts that the anti-inflammatory effect of SEL001 could be due to the presence of *myo*-inositol. Nevertheless, synergistic properties of other bioactive components existing in the SEL001 could not be ruled out.

The freeze dried extract SEL001 was also found to be effective in attenuating the miss-regulated inflammatory responses as measured by histopathological markers. The SEL001 treatment group also showed much better healing effect in disease activity measures when compared with the impact of the synthetic drug (5-ASA). Morphological signatures such as early rescue, and steady increase in body weight, a decrease in the rate of stool passage/diarrhea, inhibition of shortening of colon length, and recovery of the colon weight showed the healing potential of SEL001 for treating TNBS-induced colitis. In a similar study [@b0285] showed efficacy of ethanol extract of *Portulaca oleracea* L., for treating symptoms on dextran sulphate sodium induced UC in C57BL/6 mice model. Application of ethanol extract of *Portulaca oleracea* L. resulted in significant improvement in body weight gain and a reduction in the disease activity index scores.

Based on the course of TNBS-application, acute and chronic forms of experimental intestinal fibrosis could be induced in rodents, which mimic conditions of UC in patients. The gut inflammation in patients with UC or in TNBS-induced colitis mice is associated with the active phase inflammatory reaction and relocation of lymphocytes to the gastrointestinal tract mucosa. Chronic inflammation of colon is marked by migration of lymphocytes, and plasma cells, whereas acute inflammation results in granulocyte infiltration, local aggregation of neutrophils, eosinophilic and chemotactic mediators ([@b0110]). Neutrophil granulocytes carry multiple enzymes e.g., myeloperoxidase (MPO), which upon release from the granules confers local immunity and helps to combat bacterial infections. The MPO activity derived from the solubilized inflamed tissue is used as a direct measure of neutrophils count ([@b0110]). In this study, reduced MPO activity was observed for the SEL001 treatment group, which reflects the diminished neutrophils counts present in the tissue and shows the therapeutic-anti-inflammatory effect of SEL001.

In order to induce UC mice were administered with TNBS dissolved in ethanol. The ethanol caused initial breakdown of the epithelium and TNBS resulted in transmural inflammation of the colon ([@b0170]). The histopathology and histomorphometric assessment revealed the colitis severity and recuperation effect of SEL001 in TNBS-induced colitis mice. The histopathological inspection of TNBS-induced colitis mouse revealed features such as establishment of ulceration, mucous cell depletion, inflammatory cell infiltration, neovascularization, collagen deposition, mucosal mast cell depletion, and edematous changes, severely enhanced ([Fig. 5](#f0025){ref-type="fig"}). The marked reduction in aforementioned histopathological signs and partial or complete restoration of the normal state exhibited the therapeutic prospect of SEL001. The mucosal lining of the healthy gastrointestinal tract is composed of delicate collagen fibrils that allow the movement of mucosa over the muscularis propria ([@b0230]). It has been reported that inflammation in UC leads to the accumulation of abnormal fibrotic collagens through the abnormal deposition of extracellular matrix ([@b0230]). This phenomenon disturbs the normal relationship between mucosa, and underlying muscularis propria, which translates into a condition called as obstructive symptomatology ([@b0230]). Histopathology examination revealed that the treatment of TNBS-inflamed mice with SEL001 significantly reduced the deposition of abnormal collagen fibers, further supporting its therapeutic potential. Similar results were reported by [@b0285], where ethanol extract from *P. oleracea* exhibited protective effect on dextran sulphate sodium (DSS)-induced ulcerative colitis in mouse model ([@b0285]). In addition, ethanolic extract derived from a medicinal mashroom *Hericum erinaceus* also showed anti-inflammatory effects on DSS-induced UC. These results suggest the therapeutic potential of ethanolic extract obtained from lactic acid bacteria and medicinal herbs.

Histomorphometrical analysis revealed the decrease of mucosal mast cell population in the colon tissue after induction of UC in the experimental mice, which is the indicative of inflammation-induced loss and/or degranulation of mast cells ([@b0260]). Treatment with SEL001 partially restored mast cell population in mucosa by inhibiting the inflammation-dependent mast cell degranulation. This evidence depicts the possible anti-inflammatory role exhibited by SEL001, which could be mediated through the regulation of mast cell degranulation and associated inflammatory processes.

Pro-inflammatory cytokines such as IL-6 and TNF-α are believed to determine the degree of inflammation in UC patients. It has been reported as the expression levels of IL-6 and TNF-α increases as the severity of UC increases, suggesting a positive correlation between cytokine expression and severity of UC ([@b0005], [@b0075], [@b0265]). Treatment of TNBS-induced UC in experimental mice with 5 ASA or SEL001 greatly reduced the levels of pro-inflammatory cytokine production. Similarly, [@b0120], [@b0125] reported anti-inflammatory effects of Uro-Vaxom® a bacterial extract derived from 18 *Escherichia coli* strains containing immunostimulating components and observed that the levels of the cytokines (IL-6, IL-10, and TNF-α) in the bladder tissues were significantly changed in the experimental mice upon treatment of bacterial extract ([@b0120], [@b0125]). Mice treated with Vaxom® exhibited milder inflammation, suggesting a possible role of bioactive components present in the bacterial extract ([@b0120], [@b0125]).

The altered microbiota can directly alter and affect host health. Many probiotics are used as traditional ulcer medication, similar to the gold-standard treatment medication mesalamine probiotics has been reported to exhibit similar curative effects on the patients ([@b0115]). Similar to the earlier studies, there is substantial increase in the proportion of Proteobacteria at the expense of reduction in the proportion of phyla Firmicutes and Bacteroidetes in the colitis induced mice ([@b0150], [@b0080]). [@b0040] showed similar reduction in Firmicutes while studying dysbiosis in cattle with Jhone's disease parallel to Crohn's disease in humans. However, there is no direct report on effect of probiotics on gut microbiota of IBD/ UC to our knowledge. Increase in abundance of Firmicutes and low expression on inflammatory cytokines in SEL001 treated group indicates the positive effect of probiotic in balancing the gut microbiota and immune cells.

5. Conclusion {#s0100}
=============

In summary, in this study, SEL001 as a novel extract of probiotic-origin containing significant immunostimulating components showed promising anti-inflammatory activity in a murine model. In contrast to the detrimental side effects of the synthetic drug such as 5-ASA, the products of biological/probiotic origin such as SEL001 conferring protective anti-inflammatory effect could be considered as an attractive and safer alternative for the treatment of UC.
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